Coya Therapeutics Completes Patient Enrollment for Frontotemporal Dementia Combination Therapy Study
核心洞察
Coya Therapeutics has completed enrollment of 9 patients in an investigator-initiated study testing low-dose IL-2 and CTLA4-Ig (搜索) combination therapy for frontotemporal dementia (搜索).
The proof-of-concept study follows positive interim results from 5 patients announced in April 2025, with no serious adverse events reported to date.
Study completion is anticipated in Q4 2025, targeting a devastating neurodegenerative disease affecting approximately 30,000 Americans with limited treatment options.
Coya Therapeutics has announced the completion of patient enrollment for an investigator-initiated study evaluating a novel combination therapy for frontotemporal dementia (搜索) (FTD (搜索)), marking a significant milestone in the development of treatments for this devastating neurodegenerative disorder.
The proof-of-concept, open-label study enrolled a total of 9 patients with mild to moderate FTD (搜索), building on positive interim results from 5 patients announced in April 2025. The trial is testing a combination of low-dose interleukin-2 (IL-2) and CTLA4-Ig (搜索), administered subcutaneously, with patients receiving CTLA4-Ig followed by a 5-day course of low-dose IL-2 every four weeks for 22 weeks of dosing and follow-up.
Study Design and Safety Profile
The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (搜索) in Houston, Texas, with funding from The Peggy and Gary Edwards Endowment Fund. The trial is progressing according to protocol, with no serious adverse events or discontinuations due to safety issues reported to date.
"We are pleased to announce the completion of this important clinical milestone. FTD (搜索) is a devastating neurodegenerative disease of high unmet need. We remain committed to developing an effective and safe treatment for this rare form of dementia," commented Dr. Fred Grossman, Chief Medical Officer of Coya Therapeutics.
Addressing Significant Unmet Medical Need
Frontotemporal dementia (搜索) represents a group of neurodegenerative disorders (搜索) characterized by altered behavior and language, with progressive decline in executive function. The disease affects an estimated 30,000 Americans and is categorized into various subtypes, including behavioral-variant frontotemporal dementia and two language variants: semantic dementia and progressive non-fluent aphasia.
FTD (搜索) is classified as a presenile dementia, often occurring in younger individuals between the ages of 45 and 64. The average age of onset is 58 years, with an average survival time of 7.5 years, highlighting the urgent need for effective therapeutic interventions.
Regulatory T Cell-Focused Approach
Coya Therapeutics is developing the combination therapy as part of its broader focus on enhancing regulatory T cell (Treg) function to target neuroinflammation. The company's approach is based on the premise that dysfunctional Tregs (搜索) underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, potentially leading to sustained inflammation and oxidative stress.
Timeline and Next Steps
Study completion is anticipated in Q4 2025, with topline results to follow after database lock and analysis. The company plans to release the full results of the study following completion of data analysis, which could provide important insights into the therapeutic potential of Treg-enhancing biologics for neurodegenerative disorders (搜索).